Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.

ABSTRACT:

Background

Prader-Willi syndrome (PWS) is associated with hyperphagia and hyperghrelinemia with major morbidity because of obesity without effective medical treatment targeting hyperphagia. Exenatide (Byetta [synthetic Exendin-4]; AstraZeneca, Wilmington DE) is a GLP-1 receptor agonist which reduces appetite and weight and may be an effective treatment in PWS.

Objective

The objective of this study is to determine the effect of a 6-month trial of exenatide on appetite, weight and gut hormones in youth with PWS.

Methods

Ten overweight and obese subjects with PWS (13-25 years) were recruited for a 6-month open-label, non-randomized, longitudinal study conducted at Children's Hospital Los Angeles. Exenatide was given using standard diabetes dosing without dietary modifica

SUBMITTER: Salehi P 

PROVIDER: S-EPMC5288290 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature